A Multicenter Study on the Challenges and Real-World Utilization of Immune Checkpoint Inhibitors in Resource-Constrained Settings: Insights and Implications from India

Abstract

Using immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, but access and affordability remain significant challenges, particularly in resource-constrained settings. This multicenter study evaluated the utilization, outcomes, and challenges associated with ICIs in India. Data from multiple centers involving patients treated between January 2018 and December 2021 were retrospectively collected. Patient demographics, treatment indications, biomarker testing, financial coverage, toxicity, treatment discontinuation, clinical benefit, progression-free survival (PFS), and overall survival (OS) were analyzed. Ninety-one patients were analyzed; lung cancer (39.6%) and renal cancer (11%) were the main indications for ICI use. Programmed death ligand 1 expression was tested in 40.7% and tumor mutational burden in 3.3%. Financial constraints influenced 41.8% of patients with out-of-pocket expenses. Treatment discontinuation due to financial constraints occurred in 17.6%, with 50% showing ongoing responses. The median number of cycles was 4; the median PFS was 4.6 months, and the median OS was 15.4 months. The lung cancer cohort had a median PFS of 5.7 months and a 1-year OS of 57.6%. Limited biomarker testing and 6.6% grade ¾ toxicities were observed. This study revealed challenges in ICI utilization in resource-constrained settings driven by financial constraints. Compared with prior studies, improved outcomes reflect better patient selection and evolving understanding of ICI use. However, in the absence of biosimilars, cost remains a significant barrier. Solutions to increase access include using lower doses, which may be as effective.

Keywords

biomarker testing - checkpoint inhibitors - immunotherapy - resource-constrained settings - optimization

Note

Clinical Trials Registry-India (CTRI) Number: CTRI/2022/01/039233.

Publikationsverlauf

Eingereicht: 19. Juli 2023

Angenommen: 19. Februar 2024

Artikel online veröffentlicht:
12. April 2024

• References

• 1 Noronha V, Abraham G, Patil V. et al. A real-world data of immune checkpoint inhibitors in solid tumors from India. Cancer Med 2021; 10 (05) 1525-1534
• 2 Chandrakanth MV, Noronha V, Joshi A, Patil V, Mahajan A, Prabhash K. Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status. Indian J Cancer 2017; 54 (01) 55-56
• 3 Abbas W, Gupta S, Goel V. et al. Real-world experience of immunotherapy from India in recurrent squamous cell carcinoma of head and neck cancer. South Asian J Cancer 2021; 10 (02) 72-75
• 4 Miao K, Zhang X, Wang H. et al. Real-world data of different immune checkpoint inhibitors for non-small cell lung cancer in China. Front Oncol 2022; 12: 859938
• 5 Rini BI, Plimack ER, Stus V. et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380 (12) 1116-1127
• 6 Albiges L, Tannir NM, Burotto M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020; 5 (06) e001079
• 7 Choueiri TK, Powles T, Burotto M. et al; CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021; 384 (09) 829-841
• 8 Powles T, Park SH, Voog E. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020; 383 (13) 1218-1230
• 9 Zhang Q, Huo GW, Zhang HZ, Song Y. Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis. Open Med (Wars) 2020; 15 (01) 447-456
• 10 Mazieres J, Rittmeyer A, Gadgeel S. et al. Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol 2021; 16 (01) 140-150
• 11 Ferris RL, Blumenschein Jr G, Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375 (19) 1856-1867